ArticleCerebellum (London, England)2026
N140 Latency as a Novel Biomarker for the Evaluation of Somatosensory Dysfunction in Patients with Spinocerebellar Ataxia Type 2.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The N140 component of long-latency somatosensory evoked potentials (LL-SEPs), which is associated with passive attention, may offer a valuable adjunct to short-latency potentials (SL-SEPs) such as N20 in evaluating somatosensory function in spinocerebellar ataxia type 2 (SCA2), yet no previous studies have examined this component in this population. To address this gap, we enrolled 28 patients with SCA2 and 34 age-matched healthy controls, recording LL-SEPs (N140) from the Cz electrode referenced to linked mastoids following second-finger cutaneous stimulation, while N20 potentials were obtained via standard procedures. Clinical assessment in patients included the Scale for the Assessment and Rating of Ataxia (SARA) and CAG repeat length measurement. Compared with controls, SCA2 patients showed significantly prolonged latencies for both N140 and N20 components; however, while mean N20 amplitude was markedly reduced in patients, N140 amplitude did not differ between groups. Notably, both N140 and N20 latencies correlated positively with SARA scores. These findings indicate that the N140 potential is a valuable complement to the N20 for assessing somatosensory dysfunction in SCA2, not only because it is relatively easy to record, but more importantly because it probes higher-order cortical networks involved in cognitive somatosensory processing-networks not captured by N20. The prolonged N140 latency observed here likely reflects the defective thalamo-cortical and cerebello-cortical interactions that underpin SCA2 pathology.
Indexed as
Identifiers
42501220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.